Abstract: The present disclosure relates, in part, to immune cell targeted lipid nanoparticle (LNP) compositions, and methods of use thereof for ex vivo delivery of nucleic acid molecules and/or therapeutic agents to a target cell. In certain embodiments, the LNPs described herein are suitable for T cell activation. In certain embodiments, the nucleic acid molecules encode chimeric antigen receptors (CARs). In certain embodiments, the present disclosure relates to the use of the LNPs described herein for the treatment, prevention, and/or amelioration of diseases and/or disorders, including but not limited to cancer.

Abstract: Techniques for generating notifications with emotion-inciting images based on the context of report data, are discussed herein. A notification system may configure components and models to receive report data and analyze the report data for context data. The context data may include contextual information associated with the report data and/or a report recipient. The system may generate an image text prompt based on the context data. The system may use the image text prompt as input for an artificial intelligence (AI) image generator and receive an emotion-inciting image as output. The system may generate a notification for the report data and transmit the notification with the emotion-inciting image.

Abstract: Described herein, in part, are bisphosphonate lipid compounds, lipid nanoparticles (LNPs) thereof, and methods of use thereof. In various embodiments, the LNP selectively targets a cell of interest (e.g., a bone cell and/or bone marrow cell, such as a stem cell, stroma cell, osteoblast, osteocyte, osteoclast, bone lining cell, local mesenchymal cell, progenitor cell, mononuclear blood-borne precursor cell, B cell, endothelial cell, granulocytes, T cell, monocytic lineage, B cell lineage, monocytes, cancer cell, tumor cell, tumor cell that metastasize to bone, blood cancer cell, and multiple myeloma cell, inter alia). In other aspects, the present disclosure relates to methods for in vivo delivery of therapeutic agents to prevent or treat diseases, disorders, or conditions using the LNP compositions of the disclosure.

Abstract: Techniques for generating notifications with emotion-inciting images based on the context of report data, are discussed herein. A notification system may configure components and models to receive report data and analyze the report data for context data. The context data may include contextual information associated with the report data and/or a report recipient. The system may generate an image text prompt based on the context data. The system may use the image text prompt as input for an artificial intelligence (AI) image generator and receive an emotion-inciting image as output. The system may generate a notification for the report data and transmit the notification with the emotion-inciting image.

Abstract: In one aspect, the present disclosure relates to lipid nanoparticles (LNPs) comprising at least one ionizable lipid, at least one helper lipid, cholesterol, and at least one polymer conjugated lipid. In certain embodiments, the LNP further comprises at least one cargo molecule. In certain embodiments, the LNP comprises an epidermal growth factor (EGFR) targeting domain. In another aspect, the present disclosure provides a method of delivering a cargo to the placenta of a subject. In another aspect, the present disclosure provides a method of treating, preventing, and/or ameliorating a placental disease and/or disorder in a subject. In certain embodiments, the placental disease and/or disorder is pre-eclampsia.

Abstract: Described herein, in some aspects, are bisphosphonate lipid compounds, lipid nanoparticles (LNPs) thereof, and methods of use thereof. In various embodiments, the LNP selectively targets a cell of interest (e.g., a bone cell and/or bone marrow cell, such as a stem cell, stroma cell, osteoblast, osteocyte, osteoclast, bone lining cell, local mesenchymal cell, progenitor cell, mononuclear blood-borne precursor cell, B cell, endothelial cell, granulocytes, T cell, monocytic lineage, B cell lineage, monocytes, cancer cell, tumor cell, tumor cell that metastasizes to bone, blood cancer cell, and multiple myeloma cell, inter alia). In other aspects, the present disclosure relates to methods for in vivo delivery of therapeutic agents to prevent or treat diseases, disorders, or conditions using the LNP compositions of the disclosure.

Abstract: The present disclosure relates, in part, to siloxane-based lipids or lipidoids, lipid nanoparticles (LNPs) comprising the same, and pharmaceutical compositions thereof. In certain embodiments, the LNPs of the present disclosure selectively target cells (e.g., hepatocytes, epithelial cells, endothelial cells, and immune cells, inter alia) and/or organs of interest (e.g., liver, spleen, heart, and lungs, inter alia). In another aspect, the present disclosure relates to methods of treating, preventing, and/or ameliorating one or more diseases and/or disorders in a subject, the method comprising administering to the subject at least one LNP of the present disclosure and/or at least one pharmaceutical composition of the present disclosure.

Abstract: The disclosure relates, in part, to biodegradable lipid nanoparticles (LNPs) comprising biodegradable lipidoid compounds and compositions thereof. In certain embodiments, the LNPs selectively target a cell of interest (e.g., an immune cell, stem cell, bone cell, blood cell, fat cell, endothelial cell, cancer cell, tissue cell, nerve cell, epithelial cell, connective tissue cell, and muscle cell, inter alia). In certain embodiments, the disclosure further relates to methods for in vivo delivery of therapeutic agents for the treatment, prevention, and/or amelioration of diseases or disorders using the LNPs of the disclosure.

Abstract: A control system for a military vehicle includes processing circuitry configured to obtain a weight, an incline, a brake air supply pressure, a current gear, and a transaxle range of the military vehicle. The processing circuitry is also configured to determine a minimum brake air supply pressure for the military vehicle based on the weight, the incline, the current gear, and the transaxle range of the military vehicle. The processing circuitry is also configured to compare the brake air supply pressure to the minimum brake air supply pressure, and, in response to the brake air supply pressure being less than the minimum brake air supply pressure, operate a display of the military vehicle to provide an alarm to an operator of the military vehicle to notify the operator that the brake air supply pressure is less than the minimum brake air supply pressure.

Abstract: Porous microcarriers prepared from a poly(lactide-co-glycolide) and a porogen, which are suitable for loading of therapeutic lipid nanoparticles into the pores thereof.

Abstract: Techniques for generating notifications with emotion-inciting images based on the context of report data, are discussed herein. A notification system may configure components and models to receive report data and analyze the report data for context data. The context data may include contextual information associated with the report data and/or a report recipient. The system may generate an image text prompt based on the context data. The system may use the image text prompt as input for an artificial intelligence (AI) image generator and receive an emotion-inciting image as output. The system may generate a notification for the report data and transmit the notification with the emotion-inciting image.

Abstract: The present disclosure relates to ionizable lipidoid compounds comprising an anisamide moiety, and lipid nanoparticles (LNPs) comprising the same. In certain embodiments, the LNP selectively binds to at least one sigma receptor. In certain embodiments, the LNP specifically targets a cell of interest (e.g., a cell expressing a sigma receptor, fibroblast, cancer cell, stromal cell, and epithelial cell, inter alia). In another aspect, the present disclosure provides methods for in vivo delivery of therapeutic agents to treat, prevent, and/or ameliorate diseases and/or disorders, including but not limited to fibrosis and cancer.

Abstract: In one aspect, the present disclosure relates to lipid nanoparticles (LNPs) comprising at least one ionizable lipid, at least one helper lipid, cholesterol, at least one conjugated lipid, and at least one nucleic acid cargo (e.g., at least one mRNA and at least one sgRNA). In another aspect, the present disclosure relates to a method of delivering a cargo to the brain of a subject in need thereof. In another aspect, the present disclosure relates to methods of genome editing a mutated gene sequence associated with a disease or disorder in a subject in need thereof. In another aspect, the present disclosure relates to methods of treating a lysosomal storage disease in a subject in need thereof. In certain embodiments, the LNPs of the present disclosure are administrated in utero and/or intracerebroventricularly. In certain embodiments, the subject is embryonic, fetal, neonatal, or perinatal.

Abstract: Provided are scalable, parallelized microfluidic chips that include arrays of microfluidic mixing channels for large-scale production of lipid nanoparticles, among other products. The disclosed chips can operate with a single set of inlets and outlet, and achieve production rates in excess of those achieved by existing methods. The disclosed devices provide large-scale production of formulations while still maintaining the physical properties and potency typical of existing methods of producing such formulations. Also provided are related methods of using the disclosed devices.

Abstract: Described herein are techniques, devices, and systems for using a machine learning model(s) and/or artificial intelligence algorithm(s) to optimize testing of components of a system operated by a wireless carrier. For example, data generated as a result of executing a first test of a suite of tests may be provided as input to a trained machine learning model(s) to classify one or more tests of the suite of tests as having a particular characteristic. A to-be-executed test may be classified as likely to pass or likely to fail when executed, for example. An already-executed test may be classified as reliable or unreliable, as another example. Based on the classification of the test(s), the suite of tests may be modified to optimize testing of the wireless carrier's system.

Abstract: Systems may comprise a connectivity manager application operating on a User Equipment (UE) for optimal and secure performance of local applications and improving user experience by optimizing application performance (e.g., by prioritizing file downloads). The systems may modify data transmission of other local applications on the UE in a multi-network environment. The connectivity manager application may detect one or more network characteristics of one or more networks providing service to the UE and determine a connectivity rule based at least in part on the one or more network characteristics and/or particular data types and indicating that data transmission for the one or more transmission paths is to be adjusted, modified, paused, or prohibited in response to particular network conditions, etc.

Abstract: Described herein are techniques, devices, and systems for using a machine learning model(s) and/or artificial intelligence algorithm(s) to optimize testing of components of a system operated by a wireless carrier. For example, data generated as a result of executing a first test of a suite of tests may be provided as input to a trained machine learning model(s) to classify one or more tests of the suite of tests as having a particular characteristic. A to-be-executed test may be classified as likely to pass or likely to fail when executed, for example. An already-executed test may be classified as reliable or unreliable, as another example. Based on the classification of the test(s), the suite of tests may be modified to optimize testing of the wireless carrier's system.

Abstract: In a software testing environment, a test script may be designed to search among outputs of an in-test target application for an expected output element having a specified property. A test execution engine executes the test script, and if such an output is not found, and the test script returns a “fail” result, the test execution engine revises the test script so that rather than searching for the originally specified property, the test script searches for a different property, where the different property is a property that the expected output element was observed to have during a previous execution of the test script. The test execution engine then executes the revised test script and reports its results.

Abstract: Systems and methods for testing power consumption in user equipment (UE). The system can include devices detecting changes in power consumption due to updates in hardware, software, or both. The system can test multiple UEs to create baseline consumption measurements to detect anomalies between UEs. The system can include individual power monitoring for each UE in a “UE farm.” The system can use a workstation and a microcontroller to manage multiple UEs to perform tasks at the same time or at predetermined intervals. The system can provide benchmark testing for UEs to identify anomalies. The method can instruct multiple UEs in the UE farm to perform a particular function, run a baseline set of applications, or test new applications to identify changes in consumption caused by applications, updates, or UEs. The systems and methods can provide a standardized means for rating power consumption on mobile electronic equipment.

Abstract: A system for testing a network-based application has a continuous integration (CI) service that performs CI testing of a server application that is being developed to support a client application, such as a client application that will be used on a wireless communication device. The CI service detects server source code changes and in response rebuilds the server application and deploys it to a test server. In addition, the client application is installed and executed on one or more wireless communication devices, so that the client application communicates with the test server using a wireless communications network. Tests of the client application are performed as it executes on the devices, and results are reported to the CI service. The CI service reports any errors that occurred during testing of either the server application or the client application.